Key result
Sodium Tanshinone IIA Sulfonate lowers total cholesterol by ~1.34 mmol/L vs control in CHD patients.
Why the study?
There is no systematic review on the effectiveness and safety of Sodium Tanshinone IIA Sulfonate Injection (STS) affecting blood lipids in patients with coronary heart disease.
Does Sodium Tanshinone IIA Sulfonate Injection improve blood lipid levels in patients with coronary heart disease?
Meta-Analysis (n=2,445)
No
Does Sodium Tanshinone IIA Sulfonate Injection improve blood lipid levels in patients with coronary heart disease?
Mean Difference: -1.34 (95% CI -1.59–-1.09)
p-value: p=<0.00001
Sodium Tanshinone IIA Sulfonate Injection significantly reduces TC, TG, and LDL-c and increases HDL-c in patients with coronary heart disease, though the evidence is limited by low trial quality.
May support adjunctive lipid management in CHD; leaves open need for high-quality RCTs to confirm benefits.
Background: Lipid-lowering therapy is very important in secondary prevention of coronary heart disease (CHD). In many clinical trials, it has been found that Sodium Tanshinone IIA Sulfonate Injection (STS) have a lipid-lowering effect while reducing major cardiovascular events in patients with CHD. However, up to now, there is no system review on the effectiveness and safety of STS affecting blood lipids. Purpose: The aim of this review is to systematically assess the effects of STS on blood lipid levels in patients with CHD. Methods: Until Mar 2021, five databases (PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure, and Wanfang Database) were searched for randomized controlled trials (RCTs) about STS treating patients with CHD. Risk bias was assessed for included studies according to Cochrane handbook. The primary outcome was total cholesterol (TC). The secondary outcomes were triglycerides (TG), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), and adverse events (AEs). Results: A total of 27 trials including 2,445 CHD patients met the eligibility criteria. Most trials had high risks in random sequence generation, allocation concealment, blinding of patients and personal, blinding of outcome assessment. Meta-analysis showed that STS significantly reduced plasma TC levels [MD = −1.34 mmol/l 95% CI (−1.59, −1.09), p < 0.00001, I 2 = 98%], TG levels [MD = −0.49 mmol/l 95% CI (−0.62, −0.35), p < 0.00001, I 2 = 97%], LDL-c levels [MD = −0.68 mmol/l (−0.80, −0.57), p < 0.00001, I 2 = 96%], increased HDL-c levels [MD = 0.26 mmol/l (0.15, 0.37), p < 0.00001, I 2 = 97%], without increasing the incidence of AEs [RR = 1.27 95% CI (0.72, 2.27), p = 0.94, I 2 = 0%] in patients with CHD. Conclusion: STS can safely and effectively reduce plasma TC, TG and LDL-c levels in patients with CHD, and improve plasma HDL-c levels. However, these findings require careful recommendation due to the low overall quality of RCTs at present. More multi-center, randomized, double-blind, placebo-controlled trials which are designed follow the CONSORT 2010 guideline are needed.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2021) conducted a meta-analysis in Coronary Heart Disease (n=2,445). Sodium Tanshinone IIA Sulfonate Injection vs. Placebo, no drug, or lipid-lowering drugs (with or without routine therapy) was evaluated on Total cholesterol (TC) (MD -1.34 mmol/l, 95% CI -1.59, -1.09, p=<0.00001). Sodium Tanshinone IIA Sulfonate Injection significantly reduced plasma total cholesterol levels (MD -1.34 mmol/l) compared to control in patients with coronary heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: